In The News
Former NSW premier Berejiklian loses challenge to ICAC’s ‘serious corrupt conduct’ finding
Slater & Gordon’s bid for $12.8M cut in G8 class action needs more evidence, court told
Monsanto defeats class action alleging weed killer Roundup causes cancer
Bruce Lehrmann hires new lawyer in defamation appeal
WA home builder hit with class action over construction delays
ANZ senior execs under scrutiny in investigation over $14B bond sale
Judge says exec’s suit against Westpac a ‘private dispute’, suppresses case docs
Lendlease can’t get ex-Greenwoods partner’s damages evidence before mediation
ASIC accuses COFCO of manipulating wheat futures markets
Uber class action judge to appoint contradictor team to advise on objections to $272M settlement
ClosePlease login

Novartis unit Sandoz AG has filed an appeal after it was was barred from selling a generic version of top-selling blood clot drug Xarelto and failed to revoke two Bayer patents for the drug.

Subscribe for instant access to all Lawyerly content.

Already a subscriber?
Lost your password?

Contact us to enquire about group subscriptions.
error: Content is protected !!

For information on rights and reprints, contact subscriptions@lawyerly.com.au